Search details
1.
A herpesvirus transactivator and cellular POU proteins extensively regulate DNA binding of the host Notch signaling protein RBP-Jκ to the virus genome.
J Biol Chem
; 294(35): 13073-13092, 2019 08 30.
Article
in English
| MEDLINE | ID: mdl-31308175
2.
Autocrine TGFß Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment.
Cancer Immunol Res
; 7(2): 306-320, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30538091
3.
Targeting TGFßR2-mutant tumors exposes vulnerabilities to stromal TGFß blockade in pancreatic cancer.
EMBO Mol Med
; 11(11): e10515, 2019 11 07.
Article
in English
| MEDLINE | ID: mdl-31609088
4.
TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Cancer Chemother Pharmacol
; 83(5): 975-991, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30887178
5.
Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Article
in English
| MEDLINE | ID: mdl-29866156
6.
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-ß receptor type I inhibitor.
Oncotarget
; 9(6): 6659-6677, 2018 Jan 23.
Article
in English
| MEDLINE | ID: mdl-29467918
7.
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Drug Des Devel Ther
; 9: 4479-99, 2015.
Article
in English
| MEDLINE | ID: mdl-26309397
Results
1 -
7
de 7
1
Next >
>>